Tipifarnib is under clinical development by Johnson & Johnson and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tipifarnib’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 23 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 23 Dec 2022 increased Tipifarnib’s LoA and PTSR for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tipifarnib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tipifarnib overview

Tipifarnib (Zarnestra) is under development for the treatment of solid tumors such as non-small cell lung cancer, salivary gland cancer, recurrent head and neck cancer squamous cell carcinoma including oral cavity, pharynx, larynx, sinonasal, nasopharyngeal, or unknown primary), angioimmunoblastic T-cell lymphoma, thyroid/solid tumors with HRAS mutations, follicular T-cell lymphoma (FTCL), relapsed/refractory peripheral T cell lymphoma (PTCL), extranodal natural killer T-cell lymphoma, lower risk myelodysplastic syndrome, undifferentiated myeloproliferative disorders, chronic myelocytic leukemia, chronic myelomonocytic leukemia (CMML) and HRAS mutant urothelial cancer. The drug candidate is administered orally. It is a nonpeptidomimetic quinolinone. Tipifarnib is an inhibitor of farnesylation, a key cell signaling process implicated in cancer initiation and development.

It was also under development for the treatment of relapsed or refractory multiple myeloma, acute myeloid leukemia, advanced pancreatic cancer, higher risk myelodysplastic syndrome, breast cancer, glioblastoma multiforme, relapsed /refractory lymphomas including diffuse large b-cell lymphoma, mantle cell lymphoma, sezary syndrome , Hodgkin lymphoma, mycosis fungoides, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma),nodal marginal zone B-cell lymphoma, splenic marginal zone b-cell lymphoma,refractory anemia with excess blasts in transformation and anaplastic large cell lymphoma and Hepatitis Delta virus (HDV) infections.

Johnson & Johnson overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Quick View Tipifarnib LOA Data

Report Segments
  • Innovator
Drug Name
  • Tipifarnib
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.